3 September 2018 in Journal of Experimental & Clinical Cancer Research
Misregulation of the p53-mdm2 loop function is a major mechanism to promote hepatocellular carcinoma (HCC). RBM38, a member of the RNA recognition motif (RRM) family of RNA binding proteins (RBPs), plays a fundamental role in the posttranscriptional control of gene expression and regulatory functions in human tumors. A novel RBM38-p53-mdm2 autoregulatory feedback loop has been demonstrated. However, its mechanistic role in HCC remains unclear. In the present study, we investigated the role and molecular mechanism of misregulation in the p53-mdm2 loop function by RBM38 in HCC. First we investigated the correlation of RBM38 activity and p53-mdm2 loop function in liver cancer cells and HCC tissues by western blot and quantitative RT-PCR. We then conducted functional assays to investigate the molecular roles of RBM38 in inhibiting liver cancer cells aggressiveness in vitro and suppressing tumorigenicity in vivo. We observed RBM38 protein expression was commonly silenced coupled with increased mdm2 and decreased wild type (wt) p53 in liver cancer cells and HCC tissues compared to the corresponding normal liver cells and adjacent liver tissues. RBM38 mRNA level was significantly lower in HCC than adjacent liver tissues, whereas mdm2 and wtp53 mRNA levels were similar between HCC and adjacent liver tissues. This implied that deactivation of RBM38 could disrupt the p53-mdm2 loop and promote HCC, even though p53 and mdm2 transcript amounts were stable. Then, we generated stable liver cancer cell lines with overexpressed RBM38 (RBM38-OE) and found that up-regulation of RBM38 could inhibit mdm2 and restore wtp53 expression. Luciferase assay shown that RBM38 destabilized the mdm2 transcript through binding to multiple AU-/U-rich elements in mdm2 3’-UTR. Furthermore, functional assays showed that ectopic expression of RBM38 could induce liver cancer cell apoptosis and senescence, inhibit proliferation and colony growth, and suppress migration and invasion in vitro. Lastly, RBM38 could suppress HCC tumorigenicity in vivo. Our findings suggested that RBM38 may be a core contributor in stabilizing the p53-mdm2 loop function to prevent HCC, and a potential novel target to provide a therapeutic strategy for HCC by inhibiting mdm2 and rescuing p53 from inactivation.
12 September 2017 in BMC Cancer
Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. Between August 2004 and November 2014, 104 patients with BCLC stage B/C HCC were enrolled at the Affiliated Tumor Hospital of Guangxi Medical University, China. Forty-eight patients were treated with sorafenib alone (sorafenib group) and 56 with TACE plus sorafenib (TACE + sorafenib group). Baseline demographic/clinical data were collected. The primary outcomes were median overall survival (OS) and progression-free survival (PFS). Secondary outcomes were overall response rate (ORR) and sorafenib-related adverse events (AEs). Baseline characteristics associated with disease prognosis were identified using multivariate Cox hazards regression. The mean age of the 104 patients (94 males; 90.38%) was 49.02 ± 12.29 years. Of the baseline data, only albumin level (P = 0.028) and Child-Pugh class (P = 0.017) differed significantly between groups. Median OS did not differ significantly between the sorafenib and TACE + sorafenib groups (18.0 vs. 22.0 months, P = 0.223). Median PFS was significantly shorter in the sorafenib group than that in the TACE + sorafenib group (6.0 vs. 8.0 months, P = 0.004). Six months after treatments, the ORRs were similar between the sorafenib and TACE + sorafenib groups (12.50% vs. 18.75%, P = 0.425). The rates of grade III–IV adverse events in sorafenib and TACE + sorafenib groups were 29.2% vs. 23.2%, respectively. TACE plus sorafenib treatment (HR = 0.498, 95% CI = 0.278–0.892), no vascular invasion (HR = 0.354, 95% CI = 0.183–0.685) and Child-Pugh class A (HR = 0.308, 95% CI = 0.141–0.674) were significantly associated with better OS, while a larger tumor number was predictive of poorer OS (HR = 1.286, 95% CI = 1.031–1.604). TACE plus sorafenib treatment (HR = 0.461, 95% CI = 0.273–0.780) and no vascular invasion (HR = 0.557, 95% CI = 0.314–0.988) were significantly associated with better PFS. Compared with sorafenib alone, combining TACE with sorafenib might prolong survival and delay disease progression in patients with advanced HCC.
9 October 2020 in Research Square
Background: The accurate prediction of post-hepatectomy early recurrence (PHER) for hepatocellular carcinoma (HCC) is of great significance in determining postoperative adjuvant treatment and monitoring. This research aimed to develop and validate an artificial neural network (ANN) model to predict PHER in HCC patients without macroscopic vascular invasion.Methods: 903 patients who underwent curative liver resection for HCC were collected. They were randomly divided into a derivation cohort (n = 679) and a validation cohort (n = 224). The ANN model was then developed in the derivation cohort and verified in the validation cohort.Results: The morbidity of PHER in the derivation and validation cohorts was 34.8% and 39.2%, respectively. Multivariate analysis revealed that hepatitis B virus DNA load, γ-glutamyl transpeptadase, α-fetoprotein, tumor diameter, tumor differentiation, microvascular invasion, satellite nodules and blood loss were significantly associated with PHER. Incorporating these factors, the ANN model had greater discriminatory abilities than conventional Cox model, existing recurrence models and commonly used staging systems for predicting PHER. Stratification into two risk groups indicated a statistically significant discrepancy in recurrence-free survival curves. Conclusion: The ANN model has a significant advantage in predicting PHER for HCC patients without macroscopic vascular invasion when compared to other models and staging systems.
2 January 2026 in Frontiers in Oncology
Background: Preoperative CT features have demonstrated potential in predicting microvascular invasion (MVI) in hepatocellular carcinoma. These CT signs serve as indicators of tumor biological behavior. However, the molecular mechanisms underlying the ability of CT to preoperatively predict MVI remain largely unexplored. This study aims to elucidate the role of miR-10a-5p in HCC progression and investigate its correlation with specific imaging features. Methods: According to preoperative CT features, patients were divided into CT-MVI (+) group and CT-MVI (-) group. MiR-10a-5p expression was analyzed in HCC tissues with CT-MVI compared to those without CT-MVI. The functional effects of miR-10a-5p were assessed through in vitro cell viability and apoptosis assays, and in vivo xenograft models. Cell viability was assessed through the CCK8 assay, while flow cytometry was utilized to determine cell apoptosis. The regulatory relationships between miR-10a-5p, CD24, transferrin receptor 1 (TFR1), and STAT3 signaling were explored using western blot, luciferase reporter assays, and rescue experiments. Results: MiR-10a-5p expression was significantly downregulated in HCC tissues with CT-MVI compared to those without CT-MVI. Overexpression of miR-10a-5p reduced cell viability, promoted apoptosis, and inhibited tumor growth in vivo . MiR-10a-5p directly targeted TFR1, leading to decreased CD24 expression and reduced STAT3 phosphorylation. TFR1 overexpression partially rescued the effects of miR-10a-5p on cell apoptosis and CD24 expression. Conclusions: Our findings reveal miR-10a-5p as a key regulator of HCC progression and MVI, operating through a novel pathway involving TFR1, STAT3, and CD24. This study provides new insights into the molecular mechanisms of CT features and highlights potential therapeutic targets for HCC treatment.